Hormone replacement, peptide therapeutics, and biologic agents have moved from fringe to mainstream optimization medicine. We summarize what the controlled trials and registry data actually show — including where the evidence is strong, where it is preliminary, and where marketing has outrun the science.
Restoring a deficient hormone (low T, postmenopausal estrogen) has a different risk-benefit profile than supraphysiologic dosing for performance. Trial data rarely transfers between the two.
503A and 503B compounding pharmacies allow physicians to tailor dose, delivery, and excipients to the individual patient — critical for BHRT, pediatric dosing, allergen-free formulations, and shortage mitigation when commercial products fall short.
Hormones, peptides, and biologics all require structured baseline labs, periodic monitoring (lipids, hematocrit, IGF-1, lipid panel), and titration. 'Set and forget' dosing is a liability.
More than 80 peptide drugs are now FDA-approved across metabolic, oncologic, and regenerative indications, with hundreds more in clinical development. Targeted receptor selectivity gives peptides a favorable efficacy-to-side-effect profile compared with many small molecules.
Jarrod J. Manfro on the shift from broad pharmaceutical suppression to targeted biological signaling — and what peptides mean for longevity, recovery, and systems-based human optimization.
Manfro JJ, BioSphere Intelligence Engine, 2026
5,246 middle-aged and older men with hypogonadism and cardiovascular risk; transdermal testosterone was non-inferior to placebo for major adverse cardiac events over a mean 33 months. Higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism warrant monitoring.
Lincoff et al., NEJM, 2023 · Source ↗
Coordinated set of 7 trials in 790 men ≥65 with low T showed modest improvements in sexual function, mood, and walking distance, with mixed effects on bone density and anemia. Established the framework for current TRT trials.
Snyder et al., NEJM, 2016 · Source ↗
Reaffirms that for symptomatic women under 60 or within 10 years of menopause, benefits of MHT outweigh risks for vasomotor symptoms and bone loss. Transdermal estradiol with micronized progesterone is preferred where available.
NAMS Position Statement, Menopause, 2022 · Source ↗
Endorsed by IMS, NAMS, Endocrine Society and others: the only evidence-based indication for testosterone in women is HSDD in postmenopausal women, with target levels in the female physiologic range. No FDA-approved female product exists in the US.
Davis et al., JCEM, 2019 · Source ↗
2,539 adults without diabetes; mean weight reduction of 20.9% at 15 mg weekly over 72 weeks vs 3.1% with placebo. GI side effects were the main reason for discontinuation.
Jastreboff et al., NEJM, 2022 · Source ↗
17,604 adults with overweight/obesity and prior CVD but no diabetes; semaglutide 2.4 mg reduced MACE by 20% over a mean 39.8 months. Established cardiovascular benefit independent of glycemic effect.
Lincoff et al., NEJM, 2023 · Source ↗
Comprehensive review of the >80 FDA-approved peptide therapeutics now in clinical use across metabolic, oncologic, cardiovascular, and regenerative medicine. Highlights peptides' high target specificity, low off-target toxicity, and rapid translational pipeline — with more than 170 peptides in active clinical development and a global market projected to exceed $50B by 2030.
Wang et al., Signal Transduct Target Ther, 2022 · Source ↗
Narrative review documenting how 503A and 503B compounding pharmacies meet clinically essential needs — individualized BHRT, pediatric and geriatric dosing, dye- and allergen-free formulations, and continuity of care during FDA-recognized drug shortages. Highlights USP <795>/<797> standards and the role of state-board oversight in ensuring quality, sterility, and dose accuracy.
Watson et al., Int J Pharm Compd, 2021 · Source ↗
27,564 patients on statins; PCSK9 inhibition lowered LDL by 59% and reduced MACE by 15% over 2.2 years. Established that very low LDL (median 30 mg/dL) is safe and beneficial.
Sabatine et al., NEJM, 2017 · Source ↗
5,988 patients; SGLT2 inhibition reduced the composite of cardiovascular death or HF hospitalization by 21%, regardless of diabetes status. Reframed SGLT2 inhibitors as heart failure drugs, not just glucose-lowering agents.
Anker et al., NEJM, 2021 · Source ↗
First placebo-controlled RCT of low-dose intermittent rapamycin (5–10 mg weekly) in 114 healthy adults over 48 weeks; safety profile was acceptable with composite improvements in lean mass and pain in subgroups. Lifespan benefit remains hypothetical in humans.
Konopka et al., Aging Cell, 2025 · Source ↗
Observational data show lower all-cause mortality among diabetics on metformin vs matched non-diabetics; the TAME trial is designed to test multimorbidity outcomes in non-diabetic older adults. Until results, longevity prescribing remains off-label and pre-evidence.
Barzilai et al., Cell Metab, 2016 · Source ↗